Sensars

Sensars, with the slogan "Reviving Sensations, Restoring Life," is a pioneering startup in the field of neuromodulation for diabetic neuropathy. The company has developed SENSY, which is hailed as the first system capable of restoring natural sensations to the feet, thereby preventing complications such as ulcers, amputations, and falls, and also addressing chronic neuropathic pain. Boasting over 25 peer-reviewed publications and successful clinical studies, Sensars has secured $3.5M in undiluted grants and received a breakthrough device designation from the FDA. These achievements reflect the company's commitment to advancing its proven technology. At present, Sensars is poised to move towards pivotal trials and commercial readiness, signifying a significant milestone in its journey. Founded in 2014, Sensars operates in the industries of consumer electronics, hardware, healthcare, and medical devices. As of the most recent update, the startup received a seed investment on 6th September 2024, indicating potential interest and support from undisclosed investors. As Sensars continues to make strides in its mission, its innovative approach and promising developments position it as a noteworthy venture within the healthcare and technology sectors.